Drug Profile
Research programme: antibacterial therapeutics - Spexis
Alternative Names: Amikacin + bacterial metabolite - Spexis; EBX 001; EPP 001Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator EnBiotix
- Developer Spexis
- Class Aminoglycosides; Antibacterials
- Mechanism of Action Bacteria replacements; Bacterial growth modulators; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Pseudomonal infections; Urinary tract infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Bacterial-infections(Adjunctive treatment) in USA (IV)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Pseudomonal-infections in USA (Intranasal, Inhalant)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Urinary-tract-infections in USA